Dutasteride (Avodart) is a dual inhibitor of both type I and type II 5 alpha reductases, and thus inhibits conversion of testosterone to dihydrotestosterone, a key mediator of male pattern hair loss.
The aim of this randomized double-blind phase III study was to compare the efficacy, safety, and tolerability of dutasteride (0.5 mg) and placebo for 6 months of treatment in male patients with male pattern hair loss.
A total of 153 men, 18 to 49 years old, were randomized to receive 0.5 mg of dutasteride or placebo daily for 6 months. Efficacy was evaluated by the change of hair counts, subject assessment, and photographic assessment by investigators and panels.
Mean change of hair counts from baseline to 6 months after treatment start was an increase of 12.2/cm2 in dutasteride group and 4.7/cm2 in placebo group and this difference was statistically significant (P = .0319). Dutasteride showed significantly higher efficacy than placebo group by subject self-assessment and by investigator and panel photographic assessment. There was no major difference in adverse events between two groups.
The study was limited to 6 months.
This study clearly showed that 0.5 mg of dutasteride improved hair growth and was relatively well tolerated for the treatment of male pattern hair loss.Le texte complet de cet article est disponible en PDF.
Key words : androgenetic alopecia, dutasteride, male pattern hair loss, treatment
Abbreviations used : 5AR, DHT, HGI, MPHL
| Supported by GlaxoSmithKline.
| Conflicts of interest: None declared.